Posted by Michael Wonder on 22 Nov 2022
argenx announces US FDA acceptance of biologics license application for subcutaneous efgartigimod in generalised myasthenia gravis with priority review
22 November 2022 - PDUFA target action date is 20 March 2023.
argenx today announced the US FDA has accepted for priority review a biologics license application for subcutaneous efgartigimod (1.000mg efgartigimod-PH20) for the treatment of adult patients with generalised myasthenia gravis.
